Vanda Pharmaceuticals Inc [VNDA] Insider Polymeropoulos Mihael Hristos sells 24,288 Shares for $24,288

Vanda Pharmaceuticals Inc’s filing revealed that its President and CEO Polymeropoulos Mihael Hristos unloaded Company’s shares for reported $0.1 million on Mar 05 ’24. In the deal valued at $4.13 per share,24,288 shares were sold. As a result of this transaction, Polymeropoulos Mihael Hristos now holds 1,871,730 shares worth roughly $7.71 million.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Then, Wijkstrom Joakim sold 9,229 shares, generating $38,830 in total proceeds. Upon selling the shares at $4.21, the SVP, Chief Marketing Officer now owns 129,789 shares.

Before that, Moran Kevin Patrick sold 8,902 shares. Vanda Pharmaceuticals Inc shares valued at $37,411 were divested by the SVP, CFO & Treasurer at a price of $4.20 per share. As a result of the transaction, Moran Kevin Patrick now holds 231,014 shares, worth roughly $0.95 million.

Jefferies downgraded its Vanda Pharmaceuticals Inc [VNDA] rating to a Hold from a a Buy in a research note published on February 25, 2022; the price target was decreased to $12 from $24. A number of analysts have revised their coverage, including BofA Securities’s analysts, who began to cover the stock in mid May with a ‘”a Buy”‘ rating. Citigroup also remained covering VNDA and has decreased its forecast on January 14, 2021 with a “Neutral” recommendation from previously “Buy” rating. Citigroup revised its rating on October 29, 2020. It rated VNDA as “a Buy” which previously was an “a Neutral”.

Price Performance Review of VNDA

On Monday, Vanda Pharmaceuticals Inc [NASDAQ:VNDA] saw its stock jump 0.24% to $4.12. Over the last five days, the stock has gained 5.91%. Vanda Pharmaceuticals Inc shares have fallen nearly -2.37% since the year began. Nevertheless, the stocks have fallen -40.12% over the past one year. While a 52-week high of $7.00 was reached on 02/27/24, a 52-week low of $3.30 was recorded on 02/06/24. SMA at 50 days reached $3.99, while 200 days put it at $4.65. A total of 0.73 million shares were traded, compared to the trading of 1.37 million shares in the previous session.

Levels Of Support And Resistance For VNDA Stock

The 24-hour chart illustrates a support level at 4.06, which if violated will result in even more drops to 3.99. On the upside, there is a resistance level at 4.21. A further resistance level may holdings at 4.30. The Relative Strength Index (RSI) on the 14-day chart is 56.69, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.16, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 22.64%. Stochastics %K at 81.34% indicates the stock is a selling.

How much short interest is there in Vanda Pharmaceuticals Inc?

A steep rise in short interest was recorded in Vanda Pharmaceuticals Inc stocks on Mar 15, 2024, growing by 40000.0 shares to a total of 3.0 million shares. Yahoo Finance data shows the prior-month short interest on Feb 15, 2024 was 2.96 million shares. There was a rise of 1.33%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 6.58% of the overall stock float, the days-to-cover ratio (short ratio) rose to 3.24.

Most Popular